Much alike other peripherally administered FAAH inhibitors [12,13,41], oral ST4070 effectively reached its pharmacological target in the central nervous system, where it was able to produce a consistent inhibition of FAAH activity within anxiety-relevant brain regions. Here, FAAH is linked to Anxiety.